{"id":"W2096367061","doi":"10.1016/s1470-2045(14)70440-1","title":"Panobinostat plus bortezomib and dexamethasone versus placebo plus bortezomib and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma: a multicentre, randomised, double-blind phase 3 trial","year":2014,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Histone Deacetylase Inhibitors Research","field":"Biochemistry, Genetics and Molecular Biology","cited_by":788,"is_retracted":false,"has_abstract":false,"ca_institutions":"Queen Elizabeth II Health Sciences Centre; Dalhousie University; Hôpital Maisonneuve-Rosemont; Université de Montréal","funders":"Novartis Pharmaceuticals Corporation; Celgene; Amgen","keywords":"Panobinostat; Bortezomib; Medicine; Dexamethasone; Multiple myeloma; Placebo; Clinical endpoint; Internal medicine; Oncology; Clinical trial; Pathology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.0441648861685992,"score_gpt":0.3379999064510631,"score_spread":0.2938350202824639,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}